RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
BCBS of Vermont no longer covers any GLP-1 receptor agonists FDA-approved for weight loss as of January 1, 2026
Hims & Hers require a weight loss membership at $39 for the first month and $149/mo after that, billed separately from your medication
Preproglucagon is encoded by the GCG gene and cleaved into proglucagon
These pathways are involved in signalling fullness, regulating food intake, and influencing metabolic processes